Glenmark Pharmaceuticals Inc USA, a subsidiary of India-based Glenmark Pharmaceuticals, a global pharmaceutical company with a presence across Specialty, Generics and OTC businesses, announced on Monday that it has introduced its Fingolimod Capsules, 0.5 mg, the generic version of Novartis Pharmaceuticals' Gilenya Capsules, 0.5 mg, in the United States.
Sanjeev Krishan, president, Glenmark North America, said: "'We are very pleased to bring to market a lower cost alternative to Gilenya Capsules, 0.5 mg. This launch confirms our commitment to provide quality and affordable pharmaceutical products to patients."
The company's present portfolio includes 176 products approved for distribution in the United States marketplace and 47 ANDA's pending approval with the US FDA. The company says that it also continues to identify and explore external development collaborations to supplement and expedite the growth of its present pipeline and portfolio.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US